771 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by HB Wealth Management LLC

Key Points

• HB Wealth Management LLC invested in Alnylam Pharmaceuticals by purchasing 771 shares worth approximately $208,000 in the first quarter of the year.
• Several analysts have raised their price targets for Alnylam Pharmaceuticals, with Chardan Capital increasing its estimate from $325.00 to $400.00, reflecting a strong consensus on the company's performance.
• Alnylam Pharmaceuticals reported a 20.2% increase in revenue year-over-year, despite missing earnings expectations for the last quarter.

HB Wealth Management LLC purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 771 shares of the biopharmaceutical company's stock, valued at approximately $208,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Park Square Financial Group LLC purchased a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $28,000. Whipplewood Advisors LLC raised its holdings in Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 71 shares during the last quarter. Bessemer Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares during the period. Colonial Trust Co SC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. Finally, Washington Trust Advisors Inc. raised its stake in shares of Alnylam Pharmaceuticals by 53.5% in the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 61 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ALNY shares. Jefferies Financial Group raised their price objective on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a research note on Monday, July 7th. Oppenheimer raised shares of Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 price target for the company in a research report on Monday. JPMorgan Chase & Co. increased their target price on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a research report on Wednesday. Raymond James Financial began coverage on Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They set an "outperform" rating and a $370.00 price target for the company. Finally, Wall Street Zen raised Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Four research analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $401.12.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the sale, the chief executive officer owned 48,948 shares in the company, valued at approximately $14,978,088. This trade represents a 28.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Stock Up 2.2%

Shares of ALNY traded up $9.23 during trading on Wednesday, reaching $428.14. The company's stock had a trading volume of 1,181,793 shares, compared to its average volume of 1,167,644. The company has a fifty day moving average of $323.41 and a two-hundred day moving average of $281.19. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $428.69. The company has a market cap of $56.12 billion, a price-to-earnings ratio of -173.34 and a beta of 0.25. The company has a quick ratio of 2.98, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773,689 billion for the quarter, compared to analysts' expectations of $633.54 million. During the same quarter last year, the company earned ($0.13) EPS. Alnylam Pharmaceuticals's quarterly revenue was up 17.3% on a year-over-year basis. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.